Discovery of Genes Linked to Myeloma Onset May Drive Personalized Tx
A UK team found multiple targets of non-coding mutations, highlighting the importance of broadening the search for cancer drivers into the regulatory genome. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Morning Break: New Myeloma Tx; New EpiPen Shortage? Ticked Off by CDC
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 9, 2018 Category: Psychiatry Source Type: news

Daratumumab Now First-Line in Myeloma in US Daratumumab Now First-Line in Myeloma in US
Daratumumab becomes the first antibody approved for first-line use in the treatment of newly diagnosed multiple myeloma, in combination with three other agents.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Liquid Biopsies Instead of Bone Marrow Biopsy in Myeloma Liquid Biopsies Instead of Bone Marrow Biopsy in Myeloma
Measuring circulating tumor cells in blood samples may one day replace the painful bone marrow biopsies that are currently used to monitor disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Multiple Myeloma With Severe Abdominal Pain and Diarrhea Multiple Myeloma With Severe Abdominal Pain and Diarrhea
In this unusual case, diarrhea and abdominal pain were the initial presenting symptoms of multiple myeloma with a plasmacytoma.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Maintenance Bortezomib: No Improved Depth of Reponse in “Plateaued” MM
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Maintenance Bortezomib: No Improved Depth of Response in “Plateaued” MM
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Janssen Announces DARZALEX ® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces Darzalex (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
HORSHAM, PA, May 7, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with Velcade (bortezomib)*, a proteasome... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 7, 2018 Category: Drugs & Pharmacology Source Type: news

Newton ’s Karyopharm to seek FDA approval for cancer drug after trial win
Newton-based Karyopharm Therapeutics said Monday that it plans to seek FDA approval for its lead cancer drug later this year following the success of a mid-stage trial involving patients who had not responded to several previous treatments. Karyopharm (Nasdaq: KPTI) said that 25 percent of multiple myeloma patients in the trial had responded to treatment with the drug, called selinexor. As a result, the company announced plans to seek accelerated approval from the FDA in the second half of 2018. Shares… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 30, 2018 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Newton ’s Karyopharm to seek FDA approval for cancer drug after trial win
Newton-based Karyopharm Therapeutics said Monday that it plans to seek FDA approval for its lead cancer drug later this year following the success of a mid-stage trial involving patients who had not responded to several previous treatments. Karyopharm (Nasdaq: KPTI) said that 25 percent of multiple myeloma patients in the trial had responded to treatment with the drug, called selinexor. As a result, the company announced plans to seek accelerated approval from the FDA in the second half of 2018. Shares… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 30, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news

Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS ® (carfilzomib) Label
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies THOUSAND OAKS, Calif., April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of deat...
Source: Amgen News Release - April 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Higher Myeloma Precursor Risk in WTC Responders (CME/CE)
(MedPage Today) -- More data on 9/11 firefighter cancer risk (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 27, 2018 Category: American Health Source Type: news

Study: MS drug may diminish side effects in myeloma treatment
A drug commonly used to treat multiple sclerosis could reduce the effects of a chemotherapy of myeloma patients, according to a study of mice. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 27, 2018 Category: Consumer Health News Source Type: news

In multiple myeloma, different types of blood biopsies match up well with bone marrow tests
(Dana-Farber Cancer Institute) Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard have shown that two ways to measure multiple myeloma DNA in blood samples provide highly detailed sets of genetic information that agree well not just with each other but with results from bone marrow tests. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2018 Category: International Medicine & Public Health Source Type: news

Multiple sclerosis drug could reduce painful side effects of common cancer treatment
(Rockefeller University Press) Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2018 Category: Cancer & Oncology Source Type: news

Multiple Myeloma Risk May Be Up for WTC - Exposed Firefighters
And, cancer burden projected to be greater than expected for world trade center - exposed firefighters (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 26, 2018 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pathology, Journal, Source Type: news

Blood Cancer Precursor Found in 9/11 Firefighters
April 26, 2018—(BRONX, NY)— A study in today’s issue ofJAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma. The study was conducted by researchers atAlbert Einstein College of Medicine,Montefiore Health System, theFire Department of the City of New York (FDNY) andMemorial Sloan Kettering Cancer Center. (Source: Einstein News)
Source: Einstein News - April 26, 2018 Category: Universities & Medical Training Source Type: news

Multiple Myeloma Risk May Be Up for WTC-Exposed Firefighters
THURSDAY, April 26, 2018 -- World Trade Center-exposed firefighters have increased prevalence of monoclonal gammopathy of undetermined significance (MGUS) and light-chain MGUS, which are precursors to multiple myeloma, as well as an increased cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2018 Category: Pharmaceuticals Source Type: news

Blood cancer precursor found in 9/11 firefighters
(Albert Einstein College of Medicine) A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma. The study was conducted by researchers at Albert Einstein College of Medicine, Montefiore Health System, the Fire Department of the City of New York (FDNY) and Memorial Sloan Kettering Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2018 Category: Cancer & Oncology Source Type: news

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past
(University of Kansas) A University of Kansas research effort has resulted in a low-cost, reliable blood test that uses a small plastic chip about the size of a credit card that can deliver the same diagnostic information as a bone biopsy -- but using a simple blood draw instead. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2018 Category: Cancer & Oncology Source Type: news

Stand Up To Cancer takes new approach to multiple myeloma focusing on precursor conditions
(Entertainment Industry Foundation) A $10 million SU2C Dream Team will revolutionize treatment of multiple myeloma, through early detection of precursor conditions MGUS& SMM, before they turn into full-blown disease. Leader Irene Ghobrial, M.D., (Dana-Farber Cancer Institute) and co-leader Ivan M. Borrello, M.D., (Sidney Kimmel CCC, Johns Hopkins) will conduct a large-scale US population survey to discover biomarkers to help predict those with a high risk of progressing to multiple myeloma and then intercept disease progression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2018 Category: Cancer & Oncology Source Type: news

Quiz: Are You Aware of Multiple Myeloma –Related Disparities?
Take our latest quiz to learn about differences in MM incidence, complications, and treatment among men, women, and various racial and ethnic groups. (Source: CancerNetwork)
Source: CancerNetwork - April 10, 2018 Category: Cancer & Oncology Tags: Multiple Myeloma Quiz Source Type: news

Medical News Today: Plasmapheresis: Side effects and how it works
Plasmapheresis involves removing some plasma from the blood for donation. This plasma can be used to treat a range of medical conditions, including myeloma and some issues affecting the kidneys, the brain, or the nervous system. Here, learn how plasmapheresis works, what to expect, and how to prepare. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2018 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Excess Mortality Risk Shows Myeloma Is Still ‘Incurable’
Three year OS was significantly worse compared with the general population, with a persistent risk for relapse. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Excess Mortality Risk Shows Myeloma Is Still “Incurable”
Three year OS was significantly worse compared with the general population, with a persistent risk for relapse. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

A Novel Combination Therapy for Refractory Multiple Myeloma A Novel Combination Therapy for Refractory Multiple Myeloma
Dexamethasone can be problematic for patients with diabetes. The authors developed a novel dexamethasone-free combination regimen for multiple myeloma, which proved effective in this diabetic patient.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

High BMI in Early Adulthood Increased Myeloma Risk
A large prospective analysis of three large cohorts found a positive link between risk for myeloma and cumulative average young adult and adult BMI. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

European Commission Approves Expanded Indication For Amgen's XGEVA ® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
This Approval was Based on the Largest International Trial Ever Conducted for the Prevention of Skeletal-Related Events in Multiple Myeloma Patients THOUSAND OAKS, Calif., April 2, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events in adults with advanced malignancies involving bone. The indication now covers patients with bone metastases from solid tumors and those with multiple myeloma. The approval is based on data from the Phase 3 '482 study, the largest internat...
Source: Amgen News Release - April 3, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Blood Test Used to Diagnose Multiple Myeloma
What Blood Tests Are Used to Diagnose Multiple Myeloma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 30, 2018 Category: General Medicine Source Type: news

Ask Is there Pain with Multiple Myeloma
Is there Pain with Multiple Myeloma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 30, 2018 Category: General Medicine Source Type: news

Immunotherapy Drugs Causing Vision Issues
The U.S. Food and Drug Administration (FDA) is investigating the potential for three immunotherapy drugs to cause retinal detachment and vision loss. The FDA will consider adding eye toxicities to the warning labels for pembrolizumab (Keytruda), nivolumab (Opdivo) and ipilimumab (Yervoy), which have shown promise in clinical trials involving malignant mesothelioma. All three have already been approved by the FDA for use with metastatic melanoma. Keytruda and Opdivo also have approval for head and neck cancers, colorectal cancers and certain non-small cell lung cancers. The FDA used its Adverse Event Reporting System (FAERS...
Source: Asbestos and Mesothelioma News - March 27, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Screening high-risk individuals can reduce multiple myeloma mortality
(H. Lee Moffitt Cancer Center& Research Institute) Multiple myeloma is a rare incurable disease that is diagnosed in more than 30,000 people each year in the United States. Only half of patients with multiple myeloma are expected to survive five years after their diagnosis. Moffitt Cancer Center researchers are trying to identify patients who are at a higher risk of developing multiple myeloma early in order to improve patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 27, 2018 Category: Cancer & Oncology Source Type: news

She Was Given Three Years To Live. So She Transformed Cancer Research
In 1996, Kathy Giusti, then a 37-year-old pharmaceutical sales exec with a new baby, was told she had blood cancer, multiple myeloma, and three years to live. She refused to act like her life was over. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 26, 2018 Category: Pharmaceuticals Authors: Ellie Kincaid, Forbes Staff Source Type: news

Science Saturday: Genetic testing to enhance multiple myeloma treatment
Multiple myeloma is the second most common blood cancer, but most people haven?t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month ? a time to focus attention on the fight against multiple myeloma. Mayo Clinic is making significant advances with an individualized medicine approach. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 24, 2018 Category: Databases & Libraries Source Type: news

Pennsylvania Couple: Company Liable For Cancer From Workplace Chemical Exposure
LANCASTER, Pa. - A Pennsylvania couple filed a brief in state court on March 4 contending that their complaint against a chemical company asserts material facts that the husband was exposed to trichloroethylene (TCE) and methylene chloride (MC), which caused him to develop a form of cancer known as multiple myeloma (Paul Rogers, et al. v. Brenntag Northeast Inc., et al., No. 16-05583, Pa. Comm. Pls., Lancaster Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - March 20, 2018 Category: Medical Law Source Type: news

What Happens When the Patient Becomes the Boss?
LAGUNA NIGUEL, Calif.—Patients today have access to tools that allow them to know much more about their personal health than ever before—for better or for worse. Whether it’s the ability to look up clinical trials and new research or use wearable devices that track everything from steps to sleep quality, men and women can gather more information and bring more informed questions to their doctor. But is the medical community ready for it? At Fortune magazine’s Brainstorm Health conference, medical leaders talked about how patients can become more empowered, and the obstacles they still face. “I...
Source: TIME: Health - March 20, 2018 Category: Consumer Health News Authors: Alexandra Sifferlin Tags: Uncategorized Christi Shaw data-driven health care Dr. Eric Topol Dr. Valerie Montgomery Rice Fortune Brainstorm Health patient-centered care Source Type: news

Medical News Today: What causes Bence Jones protein in urine?
Learn about the Bence Jones protein urine test that is used to help diagnose multiple myeloma. What can you expect from the test and the results? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 13, 2018 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Ixazomib Triplet Combo Effective in R/R Myeloma
The oral therapy combination of ixazomib, pomalidomide, and dexamethasone was effective and well-tolerated in patients with myeloma that had relapsed or was refractory to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Pomalidomide/Dexamethasone Effective in R/R Myeloma With Renal Insufficiency
Nearly 80% of R/R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma Source Type: news

Medical News Today: What to eat if you have multiple myeloma
Learn about specific nutrition strategies that can be used to treat common symptoms of multiple myeloma, such as kidney damage and anemia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 28, 2018 Category: Consumer Health News Tags: Nutrition / Diet Source Type: news

Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
SAN DIEGO, Feb. 28, 2018 -- (Healthcare Sales & Marketing Network) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that Mark J. Gerg... Biopharmaceuticals, Oncology, Personnel Poseida Therapeutics, CAR T-cell, immunotherapy, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 28, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Smoldering multiple myeloma and cancer: What to know
Smoldering multiple myeloma is a rare disorder that can lead to a cancer called multiple myeloma. Learn more about the diagnosis, progression, and outlook. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 28, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Medical News Today: Stage 3 multiple myeloma: Symptoms, progression, and life expectancy
Multiple myeloma is a cancer that affects bone marrow and plasma cells. People do not usually have symptoms until they reach stage 3. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 27, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Karmanos Multiple Myeloma cancer patient and his oncologist prepare for the hike of a lifetime
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - February 23, 2018 Category: Cancer & Oncology Source Type: news

Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted THOUSAND OAKS, Calif., Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announ... Biopharmaceuticals, Oncology, Regulatory Amgen, XGEVA, denosumab, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2018 Category: Pharmaceuticals Source Type: news

Amgen Receives Positive Opinion Expanding Use Of XGEVA ® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted THOUSAND OAKS, Calif., Feb. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for XGEVA® (denosumab) to cover skeletal-related events in patients with multiple myeloma. If approved, XGEVA will be indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bon...
Source: Amgen News Release - February 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Ask Can You Die from Multiple Myeloma
Can You Die from Multiple Myeloma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 23, 2018 Category: General Medicine Source Type: news

Living With Cancer: A Cancer Researcher Takes Cancer Personally
Dr. C. Anthony Blau, who has multiple myeloma, started a company to crowdsource an individualized approach to his disease. (Source: NYT Health)
Source: NYT Health - February 15, 2018 Category: Consumer Health News Tags: Breast Cancer Clinical Trials Multiple Myeloma Research Tumors Medicine and Health Source Type: news